Results 61 to 70 of about 15,380 (223)

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, EarlyView.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source

Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients

International Journal of Hyperthermia, 2019
Background: FOLFIRINOX chemotherapy displays significant survival improvements in patients with pancreatic cancer. However, toxicities have hampered enthusiasm for the use of FOLFIRINOX in full dose.
Meng He, Jinghua Sun, Danyi Zhao, Hongmei He, Bing Wang, Lingling Xu, Yu Shang, Shanling Ren, Yang Zhang, Tao Wu   +9 more
doaj   +1 more source

mTORC2 signaling drives the development and progression of pancreatic cancer [PDF]

, 2016
mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex.
Bardeesy, Nabeel, Barry, Simon T., Driscoll, David R., Evans, T.R. Jeffry, Gay, David M., Gopinathan, Aarthi, Hall, Michael N., Jacob, Wright, Jodrell, Duncan I., Karim, Saadia A., Klimstra, David S., Lewis, Brian C., Mizukami, Yusuke, Morton, Jennifer P., Quattrochi, Brian J., Sano, Makoto, Sansom, Owen J., Yu, Jun   +17 more
core   +1 more source

Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients

Frontiers in Immunology, 2022
BackgroundBiomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies.
Fleur van der Sijde, Willem A. Dik, Dana A. M. Mustafa, Eveline E. Vietsch, Marc G. Besselink, Reno Debets, Bas Groot Koerkamp, Brigitte C. M. Haberkorn, Marjolein Y. V. Homs, Quisette P. Janssen, Saskia A. C. Luelmo, Leonie J. M. Mekenkamp, Astrid A. M. Oostvogels, Marja A. W. Smits-te Nijenhuis, Johanna W. Wilmink, Casper H. J. van Eijck, the Dutch Pancreatic Cancer Group   +16 more
doaj   +1 more source

Relationship Between Radiographic and Pathological Portal Vein‐Superior Mesenteric Vein Involvement in Neoadjuvant Treatment for Pancreatic Cancer: A Comparative Study of Neoadjuvant Chemotherapy and Chemoradiotherapy

World Journal of Surgery, EarlyView.
The relationship between the radiographic portal vein‐superior mesenteric vein (PV‐SMV) involvement and pathological PV‐SMV (pPV) invasion has been established in upfront surgery cases of pancreatic cancer (PC); however, evidence remains limited for patients receiving neoadjuvant therapy (NAT).
Naoko Sekiguchi, Hidenori Takahashi, Hirofumi Akita, Kazuki Sasaki, Shinichiro Hasegawa, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Tadafumi Asaoka, Takehiro Noda, Junzo Shimizu, Shogo Kobayashi, Yuichiro Doki, Hidetoshi Eguchi   +13 more
wiley   +1 more source

Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma [PDF]

, 2013
BACKGROUND: The standard of care in patients with metastatic pancreatic adenocarcinoma is undefined beyond second line of treatment. There have been scant reports of benefit from nab-paclitaxel in patients with refractory pancreatic cancer. MATERIALS AND
Cho, May, Gao, Feng, Peddi, Parvin F, Wang, Jian, Wang-Gillam, Andrea   +4 more
core   +2 more sources

FOLFIRINOX: From the ACCORD Study to 2014

, 2014
In the field of treatment of pancreatic cancer, there has been significant progress lately. After the ACCORD/PRODIGE-4 study, 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) became the standard combination for first-line chemotherapy.
Oikonomopoulos, G.M., Syrigos, K.N., Skoura, E., Saif, M.W.   +3 more
openaire   +2 more sources

Oxaliplatin‐induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose–response relationship and impact on quality of life

International Journal of Cancer, Volume 159, Issue 1, Page 198-209, 1 July 2026.
What's New? Oxaliplatin serves a key role in the treatment of rectal cancer, though it is a significant cause of chemotherapy‐induced peripheral neuropathy. As total neoadjuvant therapy, in which all therapy is given before surgery, has become more common, understanding neuropathy has grown increasingly important. This study examined neuropathy and its
Georg W. Wurschi, Andreas Hinz, Melanie Schneider, Jan‐Niklas Becker, Bernd Frerker, Samuel M. Vorbach, Felix Ehret, Markus Diefenhardt, Fabian Schunn, Maria‐Elena von Gruben, Marcel Büttner, Elgin Hoffmann, Alexander Rühle, Josephine Beier, Simone Ferdinandus, Maike Trommer, Ezgi Ceren Sahin, Julian Hlouschek, Kynann Aninditha, Daphne Schepers von Ohlen, Justus Kaufmann, Alina Depardon, Hai Minh Ha, Christopher Kessler, Adrianna Cieslak, Simon Trommer, Alexander Fabian, Florian Rißner, Maximilian Römer, Klaus Pietschmann   +29 more
wiley   +1 more source

COMBINATION CHEMOTHERAPY REGIMENS IN PANCREATIC CANCER

Медицинский совет, 2017
Pancreatic cancer is characterized by its aggressive behaviour and high metastatic potential, and in most cases the disease is detected in inoperable stages.
A. S. POPOVA, I. A. POKATAEV, S. A. TYULYANDIN,   +2 more
doaj   +1 more source

Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis

Journal of International Medical Research, 2022
Objective To undertake a meta-analysis of the treatment effects of different second-line chemotherapy regimens compared with FOLFIRINOX (FOL [folinic acid], F [fluorouracil], IRIN [irinotecan], OX [oxaliplatin]) after failure of gemcitabine-based first ...
Wenjie Lu, Lantian Wang, Xiawei Li, Kezhong Tang   +3 more
doaj   +1 more source